written on 09.09.2019

Allergan Launches Beauty Lab in Chengdu to Invigorate Medical Aesthetics Market

Chengdu, China, September 7, 2019 – Allergan, the leader in the global medical aesthetics industry, today launched its first consumer experience center – Allergan Beauty Lab in Chengdu Global Center, and announced to join hands with its partners in the ecosystem to explore the new trend of medical aesthetics through an innovative business model with the core mission of raising knowledge about medical aesthetics and providing immersive and customized experience for consumer. The beauty lab is a part of Allergen’s strategy to promote sustainable development of the medical aesthetics industry in China, and is expected to become a pioneering education base for the industry as well as the vast group of consumers.


Allergan Beauty Lab Grand Opening in Chengdu Global Center


The demand for medical aesthetics is growing rapidly and the market is estimated to reach CNY 500 billion (USD 70 billion) by 2022 in China, according to the Chinese medical aesthetics industry forecasts. While the enormous demand has driven the fast growth of this industry, it has also led to a chaotic market with illegal medical aesthetics practices, fake products and smuggled goods, hindering consumers in pursuing beauty. Joint efforts by various stakeholders to standardize the industry, consistently educate consumers about the industry and enhance the consumers’ recognition of medical aesthetics have become indispensable for the healthy development of the medical aesthetics industry.


Through the internationally advanced equipment and multimedia interaction, consumers can understand Allergan’s light medical aesthetics products, choose right products and learn about the market at the Allergan Beauty Lab. Allergan has been in China’s medical aesthetics market for 10 years. As Allergan’s first physical experience center in the world, the beauty lab will advance consumer’s knowledge about qualified products as well as institutions, so as to enable them to “know beauty” before “bravely pursuing beauty”.


Allergan is cooperating with Ali Health strategically to build the online flagship store to offer medical aesthetics education and consulting digitally, helping consumers to understand medical aesthetics and formal product information, as well as promoting the sustainable development of the medical aesthetics ecosystem. The Allergan Innovation Center in Chengdu and the digital platform for medical aesthetics education and consulting built jointly with Ali Health will fully benefit the medical aesthetics industry, relevant professionals and consumers from offline and online channels.



The Ribbon-cutting Ceremony of Allergan Beauty Lab


Officials from the Chengdu Hi-Tech Industrial Development Zone visited the Allergan Beauty Lab and applauded its function. Xiaoguang Qu, the director of Chinese Association of Plastics and Aesthetics (CAPA) policy research office; Jason Smith, senior vice president of Allergan and president of Allergan in Asia-Pacific, Middle-East and African region; Gerry Muhle, vice president and head of international medical aesthetics at Allergen; White Wei Wang, president of Allergan China; Xiyuan Xu ‘Big S’, famous actress; and Allergan’s partners witnessed the grand opening ceremony of Allergan Beauty Lab.


About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.

With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan’s website at www.Allergan.com.


Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2018 and Allergan’s Quarterly Report on Form 10-Q for the period ended June 30, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.